Literature DB >> 21412332

Translational medicine: Cancer lessons from mice to humans.

David Tuveson, Douglas Hanahan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21412332     DOI： 10.1038/471316a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  14 in total

1.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

2.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

3.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

4.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

Authors:  Kristian Pietras; Douglas Hanahan
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

5.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Activity of sunitinib in patients with advanced neuroendocrine tumors.

Authors:  Matthew H Kulke; Heinz-Josef Lenz; Neal J Meropol; James Posey; David P Ryan; Joel Picus; Emily Bergsland; Keith Stuart; Lesley Tye; Xin Huang; Jim Z Li; Charles M Baum; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

Review 8.  Maximizing mouse cancer models.

Authors:  Kristopher K Frese; David A Tuveson
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

Review 9.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

10.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743
View more
  37 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

Review 2.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

3.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

4.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Authors:  Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

5.  Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

Authors:  Michael R O'Dell; Jing Li Huang; Christa L Whitney-Miller; Vikram Deshpande; Paul Rothberg; Valerie Grose; Randall M Rossi; Andrew X Zhu; Hartmut Land; Nabeel Bardeesy; Aram F Hezel
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

Review 6.  Mouse hospital and co-clinical trial project--from bench to bedside.

Authors:  John G Clohessy; Pier Paolo Pandolfi
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

Review 7.  The accumulation of DNA repair defects is the molecular origin of carcinogenesis.

Authors:  Hyuk-Jin Cha; Hyungshin Yim
Journal:  Tumour Biol       Date:  2013-08-02

8.  Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.

Authors:  Peter Olson; Gerald C Chu; Samuel R Perry; Olivier Nolan-Stevaux; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

9.  Natriuretic peptide receptor A signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis.

Authors:  Jaya Mallela; Sowndharya Ravi; Frantz Jean Louis; Bianca Mulaney; Michael Cheung; Ujjwala Sree Garapati; Vignesh Chinnasamy; Chunyan Wang; Srinivas Nagaraj; Shyam S Mohapatra; Subhra Mohapatra
Journal:  Stem Cells       Date:  2013-07       Impact factor: 6.277

Review 10.  Mitochondrial metabolic reprogramming induced by calorie restriction.

Authors:  Alejandro Martin-Montalvo; Rafael de Cabo
Journal:  Antioxid Redox Signal       Date:  2012-10-15       Impact factor: 8.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.